{"id":"immediate-release-omeprazole","safety":{"commonSideEffects":[{"rate":"7","effect":"Headache"},{"rate":"5","effect":"Diarrhea"},{"rate":"4","effect":"Nausea"},{"rate":"3","effect":"Abdominal pain"},{"rate":"2","effect":"Vomiting"},{"rate":null,"effect":"Hypomagnesemia (with long-term use)"},{"rate":null,"effect":"Vitamin B12 deficiency (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1503","moleculeType":"Small molecule","molecularWeight":"345.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omeprazole is a proton pump inhibitor (PPI) that binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The immediate-release formulation allows rapid onset of acid suppression compared to delayed-release formulations.","oneSentence":"Omeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:14.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT06213818","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-03-14","conditions":"Healthy Participants","enrollment":137},{"nctId":"NCT06605950","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-10-01","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03457727","phase":"PHASE1","title":"GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":40},{"nctId":"NCT00045799","phase":"PHASE3","title":"Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-05","conditions":"Upper Gastrointestinal Bleeding","enrollment":354},{"nctId":"NCT03979989","phase":"PHASE1","title":"Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2005-09-28","conditions":"Pharmacokinetic","enrollment":32},{"nctId":"NCT02453022","phase":"PHASE1","title":"A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-05-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":18},{"nctId":"NCT00492622","phase":"PHASE4","title":"Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2007-06","conditions":"Gastroparesis, Gastroesophageal Reflux Disease","enrollment":12},{"nctId":"NCT02710994","phase":"PHASE1","title":"Pharmacodynamics and Safety of CDFR0209","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2014-05","conditions":"Stomach Ulcer, Gastroesophageal Reflux","enrollment":30},{"nctId":"NCT00961350","phase":"PHASE3","title":"A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":530},{"nctId":"NCT00960869","phase":"PHASE3","title":"Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":519},{"nctId":"NCT00995410","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Aspirin-Associated Gastric Ulcers","enrollment":380},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30},{"nctId":"NCT01015729","phase":"PHASE1","title":"Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Peptic Ulcer Disease","enrollment":30},{"nctId":"NCT00998075","phase":"PHASE1","title":"Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Peptic Ulcer Disease","enrollment":138},{"nctId":"NCT00527904","phase":"PHASE3","title":"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-03","conditions":"Gastric Ulcer","enrollment":239},{"nctId":"NCT00963027","phase":"PHASE1","title":"Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2009-09","conditions":"Hypertension, Pulmonary, Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT00749385","phase":"PHASE1","title":"A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-08","conditions":"Arthritis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Immediate-release omeprazole","genericName":"Immediate-release omeprazole","companyName":"University of Louisville","companyId":"university-of-louisville","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}